Chemocentryx Stock News

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company''s fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions.

MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released aft

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 11 th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 th at 5:00 p.m. Eastern Time.

SAN CARLOS, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will participate in a fir

The stock price of ChemoCentryx, a biopharmaceuticals company focused on orally-administered therapeutics to treat autoimmune diseases and inflammatory disorders, has seen a fall of 30% over the last

Following approval in the EU, ChemoCentryx (CCXI) plans to launch Tavneos for treating ANCA-associated vasculitis in first-half 2022.

ChemoCentryx Inc (NASDAQ: CCXI ) shares are Full story available on Benzinga.com

The European Union has approved ChemoCentryx Inc''s (NASDAQ: CCXI ) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021 . The approval covers the treatment combined with a rituximab or cyclophosphamide regimen for severe, active granulomatosis polyangiitis Full story available on Benzinga.com

ChemoCentryx Inc (NASDAQ:CCXI) shares are trading higher after the company announced EU approval of TAVNEOS for the treatment of ANCA-associated vasculitis. “European Union approval of TAVNEOS repre

The European Union has approved ChemoCentryx Inc's (NASDAQ: CCXI) Tavneos (avacopan) for ANCA-associated vasculitis. The approval follows the FDA approval of Tavneos in October 2021.

The holy grail for a biopharma company is to get a drug approved and out to market, a feat achieved by few, considering the rigorous demands of regulators. However,

Gainers: Cerus Corporation (CERS) +7%. ChemoCentryx (CCXI) +3%

After four consecutive sessions of losses, ChemoCentryx <> is on the rise after Raymond James noted the latest prescriber information on the companys ANCA vasculitis drug

G Medical Innovations (GMVD) +20%. ChemoCentryx (CCXI) +12%. Denali Therapeutics Inc. (DNLI) -13%. Immix Biopharma (IMMX) -11%.